On March 11, 2026, Eli Lilly and Company announced plans to invest approximately $3 billion over the next decade to expand its supply chain capacity in China
Documentation should reflect identity verification, informed consent for telehealth, clinical history and assessment, diagnosis, treatment rationale, and follow-up instructions
Future research is needed to study the use of obesity treatments other than AOM liraglutide and AOM semaglutide, including lifestyle interventions and use of other GLP-1 and non-GLP-1 anti-obesity medications
Smyth L, Xu D, Okar SV, Dykstra T, Rustenhoven J, Papadopoulos Z, et al